Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can anesthesia hide the trip? new study tests psilocybin for depression without the psychedelic experience

NCT ID NCT07479550

First seen Mar 18, 2026 · Last updated Jun 21, 2026 · Updated 20 times

Summary

This study tests whether giving psilocybin (a psychedelic drug) under general anesthesia can hide its mind-altering effects, allowing a truly blinded trial for depression. Ten adults with major depression will receive either psilocybin or placebo during four sessions while asleep under anesthesia. The goal is to see if this approach is safe and feasible, and to gather early data on whether it might ease depression symptoms.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Stanford University

    Stanford, California, 94304, United States

    Contact Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

psilocybin (a psychedelic compound) given under general anesthesia with propofol

What this could lead to

If it works, this could lead to a new way to study psychedelics for depression without patients knowing if they got the drug, improving research quality.

What could go wrong

This is a very small early-phase trial (10 people) testing feasibility, not effectiveness. The approach may not work or may not reduce depression symptoms.

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.